Foster Corner Drug Group in Perry, Oklahoma faced the same challenge that many independent pharmacies do. Fees and clawbacks were significantly impeding on their profits.
PDS worked with the pharmacy team to put a plan in place to mitigate DIR fees. Step one was education. With six pharmacies in the group, it was critical that they took the time to educate their teams on DIR mitigation strategies and utilizing EQuIPP and OutcomesMTM.
Every month PDS met with all members of the clinical team to discuss processes and outcomes related to their goal: improving performance and mitigating DIR fees.
Each pharmacy receives an EQuIPP report card with the latest YTD plan-level performance on adherence measures for the major plans. This allows all teams to easily identify where they are performing well, what needs improvement, and recommended action steps.
In just four months all 6 locations showed improvement in their overall CMR (comprehensive medication review) completion rate, which directly impacts DIR fees for some payers. Some locations in the group have more than doubled their rate and one location has consistently been achieving a 100% CMR completion rate for both plans they participate in.
Quality measure performance is another area that the group has seen significant improvements. They earned 29.4% of an available performance payout for a large pay-for-performance program in 2020, up from 17.6% in the prior year. One location (Foster Corner Drug) showed improvement of 23% for their statin management measure score in just 2 months and adherence scores increased by an average of 4.8% in the same time period.
This pharmacy group has shown what an engaged, educated team can achieve. DIR fee mitigation has proven to be very successful, and the pharmacies are excited to see continued success.